Gemisartan MLN 25 Tablet ER is a combination antihypertensive medication containing Cilnidipine (10 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide effective and sustained blood pressure control in patients with hypertension. Cilnidipine, a calcium channel blocker, acts by inhibiting L-type and N-type calcium channels, leading to vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output and oxygen demand. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by selectively blocking the AT1 receptor, contributing to blood pressure reduction and cardiovascular protection. The combination of these agents targets multiple pathways involved in hypertension, offering enhanced efficacy compared to monotherapy. Gemisartan MLN 25 Tablet ER is indicated for the management of essential hypertension and may be used in patients requiring combination therapy for optimal blood pressure control. The extended-release formulation ensures once-daily dosing, improving patient compliance. It should be prescribed with caution in patients with renal or hepatic impairment, and monitoring of blood pressure, renal function, and electrolytes is recommended during therapy.